Drawn by a passion for SnAP technology and all the innovative potential that it represents, our team represents an impressive and remarkable blend of breadth and depth of experience. We are committed to carving a new space in antibody design and improving the lives of patients and their families with potentially more efficacious, safer, and cost-efficient antibody-based products.
Stephanie Hsieh, J.D., M.B.A.
President, CEO, Director
Ms. Hsieh has a proven track record of setting and executing on value-building corporate strategies, particularly strategic patent portfolios.
Most recently, she held a senior position at Impax Laboratories, Inc., working with both the generic and specialty pharma divisions, leading cross-functional teams on crafting and executing on business and product strategies, including negotiating key marketing, licensing and development agreements with several major pharmaceutical companies.
Over her career she has helped devise strategies for the protection and lifecycle management of branded products, consulted to life science companies and entrepreneurs on business and patent strategies, as well as managed and prosecuted patent portfolios.
Ms. Hsieh received her M.B.A. from Stanford University and J.D. from Columbia University where she was a Harlan Fiske Stone Scholar. She received her B.A. in Biological Chemistry from Wellesley College where she graduated magna cum laude and phi beta kappa.
Robert P. McKenzie
Executive Vice President of Business Development, Director
Mr. McKenzie brings more than 25 years of experience in worldwide business development, as well as general and operational management expertise in sales and marketing, primarily in the technology industry.
Most recently, he was vice president at Amdocs, a global leader in outsourced business services, where he oversaw key global accounts in the company's Broadband, Cable and Satellite division, and was responsible for strategic planning in the cable and satellite industry, product development, business development and program delivery.
Mr. McKenzie is an internationally recognized business development professional, having orchestrated billion-dollar, transnational deals within the telecom and media industries.
He earned his B.A. in Business Economics from the University of California at Santa Barbara and serves on the board of Stanford Youth Solutions.
Chief Scientific Officer
Dr. David Stover, Ph.D. is an accomplished pharmaceutical researcher and scientist with more than 25 years of experience in both small-molecule and biologics drug discovery and development.
Most recently, he served as head of Agensys, Inc., an Astellas Pharma affiliate focused on antibody and antibody drug conjugate development, where he led a team of 240 employees in the research, clinical manufacturing and development of five investigational new drugs and four clinical proof of concepts during a 5-year period. Dr. Stover also founded the Oncology Biologics department at Novartis, where he served as its director, developing three clinical product candidates. Previously, he held the position of vice president of drug discovery at MDS Proteomics, where he managed research sites in Cambridge., Mass., Charlottesville, Va., and Toronto. Earlier in his career, Dr. Stover was the first employee and director of biochemistry at Kinetix Pharmaceuticals, a small-molecule kinase inhibitor company that was acquired by Amgen in 2000.
Dr. Stover earned his Ph.D. in biochemistry at the University of Washington and holds a Bachelor of Science degree in zoology from Duke University.
Chief Financial Officer
Mr. Hsieh has spent his entire career focused on finance and accounting including over 22 years in corporate finance investment banking.
Most recently, he was a director in the Leveraged Finance Group at BMO Capital Markets Corp., where he spent 8 years focused on the healthcare sector. He has direct experience in all forms of corporate finance including capital raising (both equity and debt) and mergers and acquisitions for all sizes of companies across a wide spectrum of industries.
Mr. Hsieh holds a B.S. in Finance from the University of Illinois in Champaign-Urbana.
Michael Goldberg, M.B.A.
Mr. Goldberg is currently a partner and director at Bain & Company, based in its Los Angeles office.
He previously held senior positions at Deloitte Consulting and Hughes Aircraft. Mr. Goldberg is a management and strategy consultant whose expertise lies in helping companies develop and implement competitive and sustainable growth strategies, as well as dramatically improving operational performance. Throughout his career, Mr. Goldberg has led significant consulting efforts in the areas of corporate growth and new market development, competitive analysis, cost reduction, asset efficiency, mergers and acquisitions, and information technology strategy, specializing in highly regulated industries, with a particular focus in aerospace and defense.
Mr. Goldberg holds an M.B.A. from the Anderson School of Business at the University of California at Los Angeles, and graduated phi beta kappa with a B.A. in economics from Occidental College. He also served as a trustee on the Occidental College Board of Trustees and chaired Occidental College's alumni fund. He currently serves as a trustee for the La Cañada Educational Foundation endowment.
Robert Kramer, Ph.D.
Dr. Kramer is an established pharmaceutical research executive with over 23 years of oncology drug discovery and development experience.
Most recently, he was Global Head of Oncology Drug Discovery at Janssen (a Johnson & Johnson company). Prior to that, he was Vice President of Oncology and Immunology Drug Discovery at Bristol-Myers Squibb from 1995 to 2010, where he oversaw the company's Princeton, New Jersey research site, including more than 250 scientists and 40 preclinical programs. Earlier in his career, Dr. Kramer served for five years as assistant professor in the Department of Radiation Therapy at Harvard Medical School, and he conducted his postdoctoral work at the National Institutes of Health.
Dr. Kramer is an accomplished scientist and researcher. He earned his Ph.D. in pharmacology at the University of Vermont and holds a B.S. in biology from SUNY at Stonybrook.
George Prendergast Ph.D.
Dr. Prendergast is an accomplished cancer researcher with experience in the pharmaceutical industry as well as in academia, recognized for his expertise in cancer biology, signal transduction and molecular therapeutics.
Throughout his career, he has become known as an innovator who has the ability to translate basic research findings toward clinical application, most recently in developing a novel drug-like therapy to improve the immune response against a cancer.
He currently is president and CEO of the Lankenau Institute for Medical Research and a professor in the Department of Pathology, Anatomy & Cell Biology, Jefferson Medical School, Thomas Jefferson University. He also is co-director of the Program in Cell Biology & Signaling, KCC, Thomas Jefferson University.
Dr. Prendergast has contributed articles to numerous publications in the field of cancer research and is inventor or co-inventor on a number of published or pending patents.